Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer

Gynecologic Oncology

Volumn 91, Issue 3, 2003, Pages 486-493

  Mathur, Subbi P ^a   Mathur, Rajesh S ^a   Underwood, Paul B ^a   Kohler, Matthew F ^a   Creasman, William T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; BIOPSY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; STUDENT T TEST; UTERINE CERVIX CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 1642373744     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.08.023     Document Type: Article

References (42)

1. Parker S.L., Tong T., Bolden S. Cancer statistics 1997. CA Cancer J Clin. 47:1997;1-27.
2. Blomfield P.I., Lancashire R.J., Woodman C.B.J. Can women at risk of cervical abnormality be identified? Br J Obstet Gynecol. 105:1998;486-492.
3. Genest D.R., Dean B., Lee K.R., Sheets E., Crum C.P., Cibas E.S. Qualifying the cytologic diagnosis of "Atypical squamous cells of undetermined significance" affects the predictive value of a squamous intraepithelial lesion on subsequent biopsy. Arch Pathol Lab Med. 122:1998;338-341.
4. Kim P.Y., Monk B.J., Chabra S., Burger R.A., Vasilev S.A., Manetta A., DiSaia P.J., Berman M.L. Cervical cancer with paraaortic metastases Significance of residual paraaortic disease after surgical staging. Gynecol Oncol. 69:1998;243-247.
5. Dassonville O., Formento I.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 11:1993;1873-1878.
6. Ozanne B., Richards C.S., Hendler F., Burns D., Gusterson B. Overexpression of EGF receptor in a hallmark of squamous cell carcinomas. J Pathol. 149:1986;9-14.
7. Pfeiffer D., Spranger J., Al-Deiri M., Kimmig R., Fisseler-Eckhoff A., Scheidel P., Schatz H., Jensen A., Pfeiffer A. mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus. Int J Cancer. 72:(4):1997;581-586.
8. Gullick W.J., Marsden J.J., Whittle N., Ward B., Bobrow L., Waterfield M.D. Expression of epidermal growth factor receptors on human cervical, ovarian and vulval carcinomas. Cancer Res. 46:1986;285-292.
9. Mittal K., Pearson J., Demopoulos R. Patterns of mRNA for epidermal growth factor receptor and keratin B-2 in normal cervical epithelium and in cervical intraepithelial neoplasia. Gynecol Oncol. 38:1990;224-229.
10. Kohler M., Janz I., Wintzer H.O., Wagner E., Bauknecht T. The expression of EGF-receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 9:1989;1537-1548.
11. Kristensen G.B., Holm R., Abeler V.M., Trope C.G. Evaluation of the prognostic significance of cathepsin D, epidermaL growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma an immunohistochemical study. Cancer. 78:(3):1996;433-440.
12. Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Meier W., Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 33:1989;146-150.
13. Kim J.W., Kim Y.T., Kim D.K., Song C.H., Lee J.W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol. 60:(2):1996;283-287.
14. Maruo T., Yamasaki M., Ladines-Llave C.A., Mochizuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer. 69:1992;1182-1187.
15. Doughaday W.H., Rohwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structure, serum and tissue concentrations. Endocr Rev. 10:1989;68-91.
16. Bell G.I., Merryweather J.P., Sanchez-Pescodor R., Stempian M.M., Priestley L., Scott J., Roll L.B. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. Nature. 310:1984;775-777.
17. Baxter R.C., Martin J.L., Beniac V.A. High molecular weight insulin-like growth factor binding protein complex. J Biol Chem. 264:1989;11843-11848.
18. Rachlar M. Insulin-like growth factor-binding proteins. Vitam Horm. 47:1993;1-114.
19. Zumkeller W. IGFs and IGFBPs surrogate markers for diagnosis and surveillance of tumor growth? Mol Pathol. 54:2001;285-288.
20. Furstenberger G., Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol. 3:2002;298-302.
21. Ayabe T., Tsutsumi O., Sakai H., Yoshikawa H., Yano T., Kurimoto F., Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J. 44:(3):1997;419-424.
22. Chan J.M., Stampfer M.J., Giovannucci E. Plasma insulin-like growth factor I and prostate cancer risk a prospective study. Science. 279:1998;563-566.
23. Hankinson S.E., Willett W.C., Colditz G.A. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 351:1998;1393-1396.
24. Peyrat J.P., Bonneterre J., Hecquet B., et al. Plasma insulin-like growth factor I (IGF-I) concentrations in human breast cancer. Eur J Cancer. 29:1993;492-497.
25. Bruning P.F., van Doorn J., Bonfrer J.M.G. Insulin-like growth factor-binding protein 3 is decreased in early stage operable premenopausal breast cancer. Int J Cancer. 2:1995;266-270.
26. Bohlike K., Cramer D.W., Trichopoulos D., et al. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 9:1998;570-573.
27. Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor I and prostate cancer risk a population-based case-control study. J Natl Cancer Inst. 90:1998;911-915.
28. Hong J., Zhang G., Dong F., Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem. 277:2002;10489-10497.
29. Naik P, Christofori G, Hanahan D. Insulin-like growth factor II is focally upregulated and functionally involved as a second signal of oncogene-induced tumorigenesis. Cold Spring Harbor Symposia on Quantitative Biology. Vol. LIX. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1994, p. 459-70.
30. Yaginuma Y., Nishiwaki K., Kitamura S., Hayashi H., Sengoku K., Ishikawa M. Relaxation of insulin-like growth factor-II gene imprinting in human gynecologic tumors. Oncology. 54:(6):1997;502-507.
31. Mathur S.P., Mathur R.S., Young R.C. Human papilloma virus (HPV) protein E6/E7 and epidermal growth factor receptor (EGF-R) levels in women with cervical cancer and CIN. Am J Reprod Immunol. 46:(4):2001;280-287.
32. Mathur R.S., Mathur S.P., Young R.C. Up regulation of epidermal growth factor receptors (EGF-R) by nicotine in cervical cancer cell lines this effect may be mediated by EGF. Am J Reprod Immunol. 44:2000;114-120.
33. Mathur R.S., Mathur S.P., Young R.C., Mathur S.P., Mathur R.S., Young R.C. Cervical epidermal growth factor-receptors (EGF-R) and serum insulin-like growth factor-II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Innumol. 44:2000;222-230.
34. Mathur S.P., Landen C.P., Datta S.M., Hoffmann M.C., Mathur R.S., Young R.C. Insulin-like growth factor II (IGF-II) in gynecological cancers a preliminary study. Am J Reprod Immunol. 49:(2):2003;113-119.
35. Van Dessell H.J.H.M., Chandrasekher Y., Yap O.W.S., Lee P.D.K., Hintz R.L., Faessen G.H.J., Braat D.D.M., Bart C., Fauser J.M., Guidice L.C. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II and IGF-binding protein -1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab. 81:1996;1224-1231.
36. Giudice L.C. Insulin-like growth factor family in Graafian follicle development and function. J Soc Gynecol Invest. 8:(1 Suppl Proceedings): 2001;S26-29.
37. Galen R.S., Gambino S.R. Beyong normality the predictive value and efficiency of medical diagnoses. 1975;Wiley, New York.
38. Irwin J.C., Suen L.F., Faessen G.H., Popovici R.M., Giudice L.C. Insulin-like growth factor (IGF)-II inhibition of endometrial stromal cell tissue inhibitor of metalloproteinase-3 and IGF-binding protein-1 suggests paracrine interactions at the decidua trophoblast interface during human implantation. J Clin Endocrinol Metab. 86:(5):2001;2060-2064.
39. Report on the nomenclature of the IGF-binding proteins. Endocrinology 130:1736:7, 1992.
40. Baxter R., Martin J. Radioimmunoassay of growth hormone-dependent insulin growth factor binding protein in human plasma. J Clin Invest. 78:1986;1504-1512.
41. Blum W.F., Ranke M.B., Kietzman K., Gouggel E., Zeisel H.J., Bierich J. A specific radioimmunoassay for the growth hormone (GH)-dependent somato medin binding protein its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 70:1990;1292-1298.
42. Probst-Hensch N.M., Yuan J.M., Stanczyk F.Z., Gao Y.T., Ross R.K., Yu M.C. IGF-1, IGF-2 and IGF-BP3 in prediagnostic serum association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer. 85:2001;1695-1699.